EGFR and cancer: Cancer cells harboring T790M represent not only resistance to EGFR-TKI but also clones proliferating relatively slowly [32], which suggested that de novo T790M predicted poor prognosis after EGFR-TKI and acquired T790M conferred superior prognosis after a long period of enrichment of T790M mutant clones.